Pretreatment patient characteristics in the training, test, and validation cohorts
| . | Training cohort (n = 163) . | Test cohort (n = 79) . | P . | Validation cohort (n = 64) . | P . |
|---|---|---|---|---|---|
| Female sex, no. (%) | 88 (54) | 46 (58) | .58 | 29 (45) | .30 |
| Median age, y (range) | 58 (17-83) | 62 (18-85) | .028 | 45 (21-59) | < .001 |
| AML type, no. | .09 | .42 | |||
| De novo AML | 156 | 71 | 64 | ||
| s-AML | 6 | 5 | 0 | ||
| t-AML | 1 | 3 | 0 | ||
| FLT3 ITD status, no. (%) | |||||
| FLT3 ITD− | 86 (53) | 57 (72) | .005 | 38 (59) | .38 |
| FLT3 ITD+ | 77 (47) | 22 (28) | 26 (41) | ||
| NPM1 status,*no. (%) | 1.00 | .01 | |||
| NPM1− | 77 (47) | 37 (47) | 18 (29) | ||
| NPM1+ | 86 (53) | 42 (53) | 45 (71) | ||
| FLT3 ITD−/ NPM1+,* no. (%) | 38 (23) | 27 (34) | .09 | 22 (35) | .09 |
| FAB classification,†no. | .14 | .52 | |||
| M0 | 5 | 1 | 1 | ||
| M1 | 45 | 23 | 16 | ||
| M2 | 45 | 34 | 13 | ||
| M4 | 42 | 11 | 22 | ||
| M5 | 19 | 6 | 9 | ||
| M6 | 6 | 3 | 0 | ||
| RAEB | 1 | 1 | 0 | ||
| Median leukocyte count, ×109/L (range) | 36.9 (0.85-486) | 15.9 (1-440.3) | .001 | 36.9 (2.1-295) | .83 |
| Median hemoglobin level, g/L (range) | 91 (40-142) | 93.5 (60-147) | .053 | 92 (60-129) | .36 |
| Median platelet count, ×109/L (range) | 56 (6-471) | 64 (9-239) | .99 | 52 (12-378) | .82 |
| Median BM blasts, % (range) | 85 (17-100) | 80 (11-97) | .31 | 64 (30-90) | < .001 |
| Median follow-up for surviving patients, mo (range) | 30 (1.6-79) | 39 (4.6-50) | 56 (47-82) | ||
| Overall survival | |||||
| Median, mo | 9.7 | 17.7 | 26.2 | ||
| Estimated OS at 2 y, % | 37 | 44 | 53 | ||
| Event-free survival,‡months | |||||
| Median, mo | 6.3 | 8.0 | 9.9 | ||
| Estimated EFS at 2 y, % | 24 | 26 | 38 | ||
| Relapse-free survival‡ | |||||
| Median, mo | 12.4 | 11.8 | 19.9 | ||
| Estimated RFS at 2 y, % | 39 | 38 | 44 | ||
| CR rate,‡ % | 62 | 65 | 84 |
| . | Training cohort (n = 163) . | Test cohort (n = 79) . | P . | Validation cohort (n = 64) . | P . |
|---|---|---|---|---|---|
| Female sex, no. (%) | 88 (54) | 46 (58) | .58 | 29 (45) | .30 |
| Median age, y (range) | 58 (17-83) | 62 (18-85) | .028 | 45 (21-59) | < .001 |
| AML type, no. | .09 | .42 | |||
| De novo AML | 156 | 71 | 64 | ||
| s-AML | 6 | 5 | 0 | ||
| t-AML | 1 | 3 | 0 | ||
| FLT3 ITD status, no. (%) | |||||
| FLT3 ITD− | 86 (53) | 57 (72) | .005 | 38 (59) | .38 |
| FLT3 ITD+ | 77 (47) | 22 (28) | 26 (41) | ||
| NPM1 status,*no. (%) | 1.00 | .01 | |||
| NPM1− | 77 (47) | 37 (47) | 18 (29) | ||
| NPM1+ | 86 (53) | 42 (53) | 45 (71) | ||
| FLT3 ITD−/ NPM1+,* no. (%) | 38 (23) | 27 (34) | .09 | 22 (35) | .09 |
| FAB classification,†no. | .14 | .52 | |||
| M0 | 5 | 1 | 1 | ||
| M1 | 45 | 23 | 16 | ||
| M2 | 45 | 34 | 13 | ||
| M4 | 42 | 11 | 22 | ||
| M5 | 19 | 6 | 9 | ||
| M6 | 6 | 3 | 0 | ||
| RAEB | 1 | 1 | 0 | ||
| Median leukocyte count, ×109/L (range) | 36.9 (0.85-486) | 15.9 (1-440.3) | .001 | 36.9 (2.1-295) | .83 |
| Median hemoglobin level, g/L (range) | 91 (40-142) | 93.5 (60-147) | .053 | 92 (60-129) | .36 |
| Median platelet count, ×109/L (range) | 56 (6-471) | 64 (9-239) | .99 | 52 (12-378) | .82 |
| Median BM blasts, % (range) | 85 (17-100) | 80 (11-97) | .31 | 64 (30-90) | < .001 |
| Median follow-up for surviving patients, mo (range) | 30 (1.6-79) | 39 (4.6-50) | 56 (47-82) | ||
| Overall survival | |||||
| Median, mo | 9.7 | 17.7 | 26.2 | ||
| Estimated OS at 2 y, % | 37 | 44 | 53 | ||
| Event-free survival,‡months | |||||
| Median, mo | 6.3 | 8.0 | 9.9 | ||
| Estimated EFS at 2 y, % | 24 | 26 | 38 | ||
| Relapse-free survival‡ | |||||
| Median, mo | 12.4 | 11.8 | 19.9 | ||
| Estimated RFS at 2 y, % | 39 | 38 | 44 | ||
| CR rate,‡ % | 62 | 65 | 84 |
P values are for the comparison between the test and training or the validation and training cohort.
s-AML indicates secondary AML after antecedent hematologic disorder; t-AML, therapy-related AML after previous chemotherapy or radiotherapy; CR, complete remission; BM, bone marrow; PB, peripheral blood.
Information on NPM1 status was missing for one patient in the validation cohort, who was FLT3 ITD negative.
FAB classification was unknown for 3 patients in the validation cohort.
Information on remission status was missing for 2 patients in the test cohort.